Oxcarbazepine-loaded polymeric nanoparticles: Development and permeability studies across in vitro models of the blood–brain barrier and human placental trophoblast

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 1985-1996

  Lopalco, Antonio ^a,b,c   Ali, Hazem ^a   Denora, Nunzio ^c   Rytting, Erik ^a,d  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c UNIVERSITY OF BARI   (Italy)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

BeWo cells; Coumarin 6; Epilepsy; HCMEC D3 cells; Nanoparticles; PLGA

Indexed keywords

NANOPARTICLE; OXCARBAZEPINE; POLYGLACTIN; RESOMER; CARBAMAZEPINE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; BLOOD BRAIN BARRIER; BLOOD PLACENTA BARRIER; CONTROLLED STUDY; CRYOELECTRON MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; TROPHOBLAST; X RAY DIFFRACTION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CELL LINE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; FEMALE; METABOLISM; PLACENTA; PREGNANCY;

BLOOD-BRAIN BARRIER; CARBAMAZEPINE; CELL LINE; CELL MEMBRANE PERMEABILITY; FEMALE; HUMANS; LACTIC ACID; NANOPARTICLES; PLACENTA; POLYGLYCOLIC ACID; PREGNANCY; TROPHOBLASTS;

EID: 84933557716     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S77498     Document Type: Article

References (37)

1. Tomson T, Danielsson BR, Winbladh B. Epilepsi och graviditet. En balansgång mellan risker för mor och barn. [Epilepsy and pregnancy. Balancing between risks to the mother and child]. Läkartidningen 1997;94:2827–2835. Swedish.
2. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11:803–813.
3. Reimers A, Brodtkorb E. Second-generation antiepileptic drugs and pregnancy: a guide for clinicians. Expert Rev Neurother. 2012;12: 707–717.
4. Rolnitsky A, Merlob P, Klinger G. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. Pediatr Neurol. 2013;48:466–468.
5. Wlodarczyk BJ, Palacios AM, George TM, Finnell RH. Antiepi-leptic drugs and pregnancy outcomes. Am J Med Genet A. 2012; 158A:2071–2090.
6. Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305:1996–2002.
7. Battino D, Tomson T. Management of epilepsy during pregnancy. Drugs. 2007;67:2727–2746.
8. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261:579–588.
9. Myllynen P, Pienimaki P, Jouppila P, Vahakangas K. Transplacen-tal passage of oxcarbazepine and its metabolites in vivo. Epilepsia. 2001;42:1482–1485.
10. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand. 1993;87:224–227.
11. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40:648–677.
12. Vorbrodt AW, Dobrogowska DH. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron micros-copist’s view. Brain Res Brain Res Rev. 2003;42:221–242.
13. Sastry BV. Techniques to study human placental transport. Adv Drug Deliv Rev. 1999;38:17–39.
14. Dilworth MR, Sibley CP. Review: transport across the placenta of mice and women. Placenta. 2013;34(Suppl):S34–S39.
15. Enders AC, Blankenship TN. Comparative placental structure. Adv Drug Deliv Rev. 1999;38:3–15.
16. Audus KL. Controlling drug delivery across the placenta. Eur J Pharm Sci. 1999;8:161–165.
17. Denora N, Laquintana V, Lopalco A, et al. In vitro targeting and imaging the translocator protein TSPO 18-kDa through G(4)-PAMAM-FITC labeled dendrimer. J Control Release. 2013;172:1111–1125.
18. Denora N, Trapani A, Laquintana V, Lopedota A, Trapani G. Recent advances in medicinal chemistry and pharmaceutical technology – strategies for drug delivery to the brain. Curr Top Med Chem. 2009;9:182–196.
19. Liu Y, Guo Y, An S, et al. Correction: targeting caspase-3 as dual therapeutic benefts by RNAi facilitating brain-targeted nanoparticles in a rat model of Parkinson’s disease. PLoS One. 2013;8:e62905.
20. Li J, Feng L, Fan L, et al. Targeting the brain with PEG-PLGA nanoparticles modifed with phage-displayed peptides. Biomaterials. 2011;32:4943–4950.
21. Bennewitz MF, Saltzman WM. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics. 2009;6:323–336.
22. Chen Z, Penet MF, Nimmagadda S, et al. PSMA-targeted thera-nostic nanoplex for prostate cancer therapy. ACS Nano. 2012;6: 7752–7762.
23. Gwenin VV, Gwenin CD, Kalaji M. Colloidal gold modifed with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy. Langmuir. 2011;27:14300–14307.
24. Saunders M. Transplacental transport of nanomaterials. Wiley Interdis-cip Rev Nanomed Nanobiotechnol. 2009;1:671–684.
25. Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure. 2010; 19:112–119.
26. Beck-Broichsitter M, Rytting E, Lebhardt T, Wang X, Kissel T. Preparation of nanoparticles by solvent displacement for drug delivery: a shift in the “ouzo region” upon drug loading. Eur J Pharm Sci. 2010;41:244–253.
27. Poulsen MS, Rytting E, Mose T, Knudsen LE. Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. Toxicol In Vitro. 2009;23:1380–1386.
28. Dauchy S, Miller F, Couraud PO, et al. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol. 2009;77:897–909.
29. Ragnaill MN, Brown M, Ye D, et al. Internal benchmarking of a human blood–brain barrier cell model for screening of nanoparticle uptake and transcytosis. Eur J Pharm Biopharm. 2011;77:360–367.
30. Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mader K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, feld-fow fractionation and transmission electron microscopy. J Control Release. 2004;95:217–227.
31. Sherman MB, Weaver SC. Structure of the recombinant alphavirus Western equine encephalitis virus revealed by cryoelectron microscopy. J Virol. 2010;84:9775–9782.
32. Lepault J, Booy FP, Dubochet J. Electron microscopy of frozen biological suspensions. J Microsc. 1983;129:89–102.
33. Bode CJ, Jin H, Rytting E, Silverstein PS, Young AM, Audus KL. In vitro models for studying trophoblast transcellular transport. Methods Mol Med. 2006;122:225–239.
34. Cartwright L, Poulsen MS, Nielsen HM, et al. In vitro placental model optimization for nanoparticle transport studies. Int J Nanomedicine. 2012;7:497–510.
35. Morck TJ, Sorda G, Bechi N, et al. Placental transport and in vitro effects of Bisphenol A. Reprod Toxicol. 2010;30:131–137.
36. Ali H, Kalashnikova I, White MA, Sherman M, Rytting E. Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model. Int J Pharm. 2013;454:149–157.
37. Lu JM, Wang X, Marin-Muller C, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9:325–341.